Trial reportBlood2019
Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 85 citations in OpenAlex.
- Trial
- Cerebral oxygen metabolism in adults with sickle cell disease.American journal of hematology · 2020Trial
- Reliability of diffuse optical spectroscopies for evaluation of cerebral hemometabolic stress in children with sickle cell anemia.Biomedical optics express · 2026Article
- Regional brain age is decreased in children with sickle cell anemia.Blood advances · 2026Article
- Review
- Cerebral blood flow trajectories in paediatric sickle cell anaemia by age, region, and treatment associations.British journal of haematology · 2026Article
- Elevated cerebral blood flow in distal and intermediate arterial territories in pediatric sickle cell anemia.Frontiers in neuroscience · 2026Article
- Chronic Hydroxyurea Therapy in Children with Sickle Cell Anemia: Mechanisms of Action, Systemic Effects, and Long-Term Safety.Journal of clinical medicine · 2025Review
- Article
- Comparison of cerebral oxygen extraction fraction using ASE and TRUST methods in patients with sickle cell disease and healthy controls.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Reversibility of Cognitive Deficits and Functional Connectivity With Transfusion in Children With Sickle Cell Disease.Neurology · 2024Article
- Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease.Blood advances · 2024Article
- Article
- Molecular and environmental contributors to neurological complications in sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Measurement of Cerebral Oxygen Extraction Fraction Using Quantitative BOLD Approach: A Review.Phenomics (Cham, Switzerland) · 2023Review
- Article
- Silent infarction in sickle cell disease is associated with brain volume loss in excess of infarct volume.Frontiers in neurology · 2023Article
- Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives.Journal of blood medicine · 2023Review
- Effect of Blood Transfusion on Cerebral Hemodynamics and Vascular Topology Described by Computational Fluid Dynamics in Sickle Cell Disease Patients.Brain sciences · 2022Article
- Cerebral oxygen extraction fraction MRI: Techniques and applications.Magnetic resonance in medicine · 2022Review
Corrections and comments
- Commented on byBrain O2019
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic transfusion therapy (CTT) prevents stroke in selected patients with sickle cell anemia (SCA). We have shown that CTT mitigates signatures of cerebral metabolic stress, reflected by elevated oxygen extraction fraction (OEF), which likely drives stroke risk reduction. The region of highest OEF falls within the border zone, where cerebral blood flow (CBF) nadirs; OEF in this region was reduced after CTT. The neuroprotective efficacy of hydroxyurea (HU) remains unclear. To test our hypothesis that patients receiving HU therapy have lower cerebral metabolic stress compared with patients not receiving disease-modifying therapy, we prospectively obtained brain magnetic resonance imaging scans with voxel-wise measurements of CBF and OEF in 84 participants with SCA who were grouped by therapy: no disease-modifying therapy, HU, or CTT. There was no difference in whole-brain CBF among the 3 cohorts (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.